In recent years, a breakthrough was made in the targeting of the three main members of the B7 family, CTLA-4, PD-1 and PD-L1 (B7-H1), in the immune checkpoint blockade treatment of cancer [13]. The gene discussed is CTLA4; the disease is cancer.